Decline in peripheral blood NKG2D+CD3+CD56+NKT cells in metastatic colorectal cancer patients

作者：Gharagozloo M; Rezaei A; Kalantari H; Bahador A; Hassannejad N; Maracy M; Nouri N; Sedghi M; Ghazanfari H^*; Bayat B

来源：Bratislava Medical Journal, 2018, 119(1): 6-11.

DOI：10.4149/BLL_2018_002

• low-grade non-metastatic colorectal cancer
• high-grade non-metastatic colorectal cancer
• metastatic colorectal cancer
• CD3+CD56+NKT cells
• NKG2D

OBJECTIVE: Colorectal cancer (CRC) is one of the main causes of cancer deaths in the world. This cancer can be divided into non-metastatic and metastatic CRC stages. CD3+CD56+ NKT cell subsets are a minor T cell subset in peripheral blood and conduct the killing of tumor cells in direct manner. Little is obvious about levels and surface markers of these cells such as NKG2D in different cancers, especially in CRC.
METHODS: We included 15 non-metastatic (low-grade), 11 non-metastatic (high-grade), 10 metastatic colorectal cancer patients and 18 healthy controls. The percentages of CD3+CD56+ NKT cells and NKG2D+CD56+ NKT cells from samples were analyzed by flow cytometry in peripheral blood mononuclear cells (PBMCs) of samples.
RESULTS: We found that there was a significantly lower number of NKG2D+CD3+CD56+ cells in peripheral blood of patients with metastatic colorectal cancer compared with normal controls (77.53 +/- 5.79 % vs 90.74 +/- 9.84 %; p<0.01).
CONCLUSION: The fact that frequency of NKG2D+CD56+ NKT cells was significantly lower in patients with metastatic colorectal cancer compared to healthy controls strengthens the hypothesis that NKT cells can play a substantial role in the protection against human colorectal cancer, and this opens up avenues for novel studies about elucidating the other aspects of tumor surveillance in CRC progression and immunotherapy.

• 出版日期2018